ORMP - オラメド・ファ―マシュ―ティカルズ （Oramed Pharmaceuticals Inc.） オラメド・ファ―マシュ―ティカルズORMPのチャート
ORMPの企業情報
| symbol | ORMP |
|---|---|
| 会社名 | Oramed Pharmaceuticals Inc （オラメド・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product an orally ingestible insulin capsule in phase II clinical trials is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed’s delivery platform protects protein sand enhances their absorption allowing them to reach the blood stream through the portal vein. The Company’s products include ORMD-0801 Oral insulin capsule; ORMD 0901 Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B. オラメド・ファ―マシュ―ティカルズは、イスラエルの製薬会社。経口投与ソリュ―ションの開発を手掛ける。糖尿病治療用経口インスリンをはじめ、他の薬剤やワクチンの投与ソリュ―ションも開発する。主な製品は、経口インスリンカプセル剤の｢ORMD-0801｣や経口エクセナチドカプセルの｢ORMD-0901｣。本社はエルサレム。 oramed pharmaceuticals (nasdaqcm:ormp) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 trials under the usfda, the company is seeking to revolutionize the treatment of diabetes. read more: http://www.oramed.com/investors/corporate-presentation watch: https://www.youtube.com/watch?v=5qchxtdv9eg |
| 本社所在地 | 142 W. 57th Street New York NY 10019 USA |
| 代表者氏名 | Kevin L. Rakin ケヴィン・L・ラッキン |
| 代表者役職名 | Chairman of the Board Independent Director |
| 電話番号 | +972 2-566-0001 |
| 設立年月日 | 37347 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 14人 |
| url | www.oramed.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ormp |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -13.22500 |
| 終値（lastsale） | 4.7 |
| 時価総額（marketcap） | 81604290.5 |
| 時価総額 | 時価総額（百万ドル） 74.13837 |
| 売上高 | 売上高（百万ドル） 2.45000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 50.76537 |
| 当期純利益 | 当期純利益（百万ドル） -12.49700 |
| 決算概要 | 決算概要 BRIEF: For the nine months ended 31 May 2018 Oramed Pharmaceuticals Inc. revenues remained flat at $1.8M. Net loss increased 26% to $9.8M. Revenues reflect market conditions. Higher net loss reflects RESEARCH AND DEVELOPMENT EXPENSES increase of 19% to $9.2M (expense) GENERAL AND ADMINISTRATIVE EXPENSES increase of 67% to $3.1M (expense) FINANCIAL EXPENSES increase of 11% to $72K (expense). |
ORMPのテクニカル分析
ORMPのニュース
China to launch world’s first oral insulin for Type-2 diabetes: Report 2023/05/27 21:20:51 Nagaland Post
China is soon likely to become the world’s first country with oral insulin availability. After successfully completing Phase III trials of oral insulin, China’s Hefei Tianhui Biotechnology (HTIT) submitted a marketing authorisation application (MAA) to the country’s National Medical Products Administration. Oramed’s US-based ORA-D-013-1 Phase III trial for the treatment of Type 2 diabetes showed significant lowering of A1C levels, which reflects the average blood sugar level for the past two to three months. HTIT is a strategic partner of Israeli company Oramed Pharmaceuticals. “Oral insulin is a paradigm shift from the traditional injectable insulin market. Therefore, there would be a lot of opportunities and challenges in the commercialisation of oral insulins,” said Prashant Khadayate, Pharma Analyst at GlobalData, in a statement. “Even though insulin delivery through injections has improved significantly for patients, compliance is always an issue for injectable forms of insulin. Hence, oral insulin will always be preferred, potentially reducing the discomfort associated with injections and thereby, improving overall compliance, provided it is equally effective in terms of efficacy and safety.
Canaccord Genuity maintains Oramed at ''hold'' with a price target of $2.00 2023/05/17 11:25:36 Investing.com
https://www.investing.com/news/pro/oramed-pharmaceuticals-inc-receives-investment-bank-analyst-rating-update-3084634
Oramed Surges on New Diabetes Treatment 2023/05/15 20:19:36 TipRanks
Fighting either type of diabetes is a challenge that can follow some around for their entire lives. That’s why news out of healthcare stock Oramed …
Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday''s Mid-Day Session 2023/05/15 17:45:31 Benzinga
Gainers NeoGames S.A. (NASDAQ: NGMS ) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash. 1847 Holdings LLC (NASDAQ: EFSH ) gained 64.5% to $0.9050 after the company reported a 27.6% increase in revenue to $15.4 million and achieved profitability for the first quarter. Harbor Custom Development, Inc. (NASDAQ: HCDI ) surged 49.5% to $8.97 following first-quarter results. WiSA Technologies, Inc. (NASDAQ: WISA ) rose 47.4% to $2.33 after the company signed a Letter of Intent to acquire Comhear. WiSA expects acquisition to be accretive beginning in the fourth quarter and sees FY24 revenue of $10 million to $15 million. Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) gained 39% to $3.94 as the company said that its Chinese partner, HTIT, has successfully completed a Phase 3 oral insulin clinical trial and submitted a marketing authorization application in China. LM Funding America, Inc. (NASDAQ: LMFA ) jumped 34% to $0.9816 following better-than-expected results for the first quarter.
Why Oramed Pharmaceuticals Shares Are Trading Higher Today 2023/05/15 15:18:10 Benzinga
Oramed Pharmaceuticals Inc (NASDAQ: ORMP ) shares are trading higher after its partner completed Phase 3 trials of oral insulin in type 2 diabetes in China under a differentiated study protocol . Hefei Tianhui Biotechnology Co Ltd , a strategic partner of Oramed, is moving toward regulatory approval and has submitted the data to the National Medical Products Administration. Oramed has recently … Full story available on Benzinga.com
China to launch world’s first oral insulin for Type-2 diabetes: Report 2023/05/27 21:20:51 Nagaland Post
China is soon likely to become the world’s first country with oral insulin availability. After successfully completing Phase III trials of oral insulin, China’s Hefei Tianhui Biotechnology (HTIT) submitted a marketing authorisation application (MAA) to the country’s National Medical Products Administration. Oramed’s US-based ORA-D-013-1 Phase III trial for the treatment of Type 2 diabetes showed significant lowering of A1C levels, which reflects the average blood sugar level for the past two to three months. HTIT is a strategic partner of Israeli company Oramed Pharmaceuticals. “Oral insulin is a paradigm shift from the traditional injectable insulin market. Therefore, there would be a lot of opportunities and challenges in the commercialisation of oral insulins,” said Prashant Khadayate, Pharma Analyst at GlobalData, in a statement. “Even though insulin delivery through injections has improved significantly for patients, compliance is always an issue for injectable forms of insulin. Hence, oral insulin will always be preferred, potentially reducing the discomfort associated with injections and thereby, improving overall compliance, provided it is equally effective in terms of efficacy and safety.
Canaccord Genuity maintains Oramed at ''hold'' with a price target of $2.00 2023/05/17 11:25:36 Investing.com
https://www.investing.com/news/pro/oramed-pharmaceuticals-inc-receives-investment-bank-analyst-rating-update-3084634
Oramed Surges on New Diabetes Treatment 2023/05/15 20:19:36 TipRanks
Fighting either type of diabetes is a challenge that can follow some around for their entire lives. That’s why news out of healthcare stock Oramed …
Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday''s Mid-Day Session 2023/05/15 17:45:31 Benzinga
Gainers NeoGames S.A. (NASDAQ: NGMS ) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash. 1847 Holdings LLC (NASDAQ: EFSH ) gained 64.5% to $0.9050 after the company reported a 27.6% increase in revenue to $15.4 million and achieved profitability for the first quarter. Harbor Custom Development, Inc. (NASDAQ: HCDI ) surged 49.5% to $8.97 following first-quarter results. WiSA Technologies, Inc. (NASDAQ: WISA ) rose 47.4% to $2.33 after the company signed a Letter of Intent to acquire Comhear. WiSA expects acquisition to be accretive beginning in the fourth quarter and sees FY24 revenue of $10 million to $15 million. Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) gained 39% to $3.94 as the company said that its Chinese partner, HTIT, has successfully completed a Phase 3 oral insulin clinical trial and submitted a marketing authorization application in China. LM Funding America, Inc. (NASDAQ: LMFA ) jumped 34% to $0.9816 following better-than-expected results for the first quarter.
Why Oramed Pharmaceuticals Shares Are Trading Higher Today 2023/05/15 15:18:10 Benzinga
Oramed Pharmaceuticals Inc (NASDAQ: ORMP ) shares are trading higher after its partner completed Phase 3 trials of oral insulin in type 2 diabetes in China under a differentiated study protocol . Hefei Tianhui Biotechnology Co Ltd , a strategic partner of Oramed, is moving toward regulatory approval and has submitted the data to the National Medical Products Administration. Oramed has recently … Full story available on Benzinga.com
Oramed Pharmaceuticals Inc. (ORMP) produces promising results 2023/03/03 13:24:00 US Post News
A share of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) closed at $2.13 per share on Thursday, down from $2.20 day before. While Oramed Pharmaceuticals Inc. has underperformed by -3.18%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ORMP fell by -78.48%, with highs and lows ranging from $13.73 […]
Wondrous stocks: BP p.l.c. (NYSE:BP 1.93%), Oramed Pharmaceuticals Inc. (NASDAQ:ORMP -0.95%) 2023/02/24 13:24:24 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Wondrous stocks: BP p.l.c. (NYSE:BP 1.93%), Oramed Pharmaceuticals Inc. (NASDAQ:ORMP -0.95%) appeared first on Stocks Equity .
Wondrous stocks: Oramed Pharmaceuticals Inc. (NASDAQ:ORMP -1.36%), Ouster, Inc. (NYSE:OUST -1.29%) 2023/02/13 07:18:32 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Wondrous stocks: Oramed Pharmaceuticals Inc. (NASDAQ:ORMP -1.36%), Ouster, Inc. (NYSE:OUST -1.29%) appeared first on Stocks Equity .
Exploring Growth Opportunities In Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) 2023/02/09 15:00:00 Stocks Register
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) shares, rose in value on Wednesday, 02/08/23, with the stock price up by 1.46% to the previous day’s close as strong demand from buyers drove the stock to $2.08. Actively observing the price movement in the last trading, the stock closed the session at $2.05, falling within a range of $2.025 … Exploring Growth Opportunities In Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) Read More »
Astonishing stocks: Oramed Pharmaceuticals Inc. (NASDAQ:ORMP -1.44%), Draganfly Inc. (NASDAQ:DPRO -12.77%) 2023/02/08 11:46:15 Stock Equity
ORMP has seen its SMA50 which is now -70.74%. In looking the SMA 200 we see that the stock has seen a -69.77%. DPRO has seen its SMA50 which is … The post Astonishing stocks: Oramed Pharmaceuticals Inc. (NASDAQ:ORMP -1.44%), Draganfly Inc. (NASDAQ:DPRO -12.77%) appeared first on Stocks Equity .